Enhanced Endothelial Delivery and Biochemical Effects of α-Galactosidase by ICAM-1-Targeted Nanocarriers for Fabry Disease

Fabry disease due to deficiency of α-galactosidase A (α-Gal) causes lysosomal accumulation of globotriaosylceramide (Gb3) in multiple tissues and prominently in the vascular endothelium. Although enzyme replacement therapy (ERT) by injection of recombinant α-Gal improves the disease outcome, effects...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Hsu, Janet, Serrano, Daniel, Bhowmick, Tridib, Kumar, Kishan, Shen, Yang, Kuo, Yuan Chia, Garnacho, Carmen, Muro, Silvia
Format: Artigo
Langue:Inglês
Publié: 2010
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3073729/
https://ncbi.nlm.nih.gov/pubmed/21047542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2010.10.031
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires